Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving erlotinib together with sorafenib works in
treating patients with progressive or recurrent glioblastoma multiforme. Erlotinib and
sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor. Giving erlotinib together with sorafenib may
kill more tumor cells.